Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Note: The response rates in this study either alone or in combination were low. The side effects appear to be understated (abstract).